Cambridge Healthtech Institute’s Inaugural

Oligonucleotide and Peptide CMC and Manufacturing

Advancing Scalable, Sustainable Platforms to Meet Growing Demand

August 11-12, 2026

Broadening applications of oligonucleotides and the explosive demand for GLP-1s are fueling urgent innovation in manufacturing approaches that balance both scale and sustainability. Cambridge Healthtech Institute’s Inaugural Oligonucleotide and Peptide CMC and Manufacturing conference convenes experts from the worlds of bioprocessing and process chemistry to explore the latest developments in synthetic, hybrid, and recombinant production platforms, as well as CMC and analytical strategies to improve the development and manufacturing of ASOs, siRNAs, gRNAs, peptide therapeutics, related conjugates, and beyond. Sessions will highlight emerging developments in CMC, analytics, regulatory expectations, solid- and liquid-phase synthesis, upstream and downstream processing, continuous purification, green chemistry, drug product and formulation, and overcoming challenges with conjugated and non-canonical molecules.

Coverage will include, but is not limited to:

Scaling synthetic, hybrid and recombinant platforms for oligonucleotide manufacturing: synthesis and purification

Integrating solid- and liquid-phase synthesis to improve yield and reduce solvent usage

Advances in hybrid and enzymatic methods for scalable ASO, siRNA, gRNA production

Process intensification strategies for sustainability and cost control

Overcoming bottlenecks in purification and oligo conjugation

Simplifying complex supply chains and scaling to kg production
- CMC, Control Strategies, and Analytics for Complex Oligonucleotides, including conjugates
Regulations and standards for oligonucleotides

Developing robust analytical and CMC frameworks for chemically modified and conjugated oligos

Advanced analytical tools for impurity profiling and sequence confirmation

Lifecycle management: linking process development to regulatory expectations

Case studies on establishing control strategies for high-throughput oligo manufacturing
- Peptide Process Innovation in the Era of GLP-1 Demand
Scaling peptide synthesis: optimizing SPPS, LPPS, and hybrid methods

Continuous purification and green chemistry solutions to reduce cost and waste

Engineering solutions for large-scale GLP-1 and other complex peptide APIs

Leveraging automation and digital tools for rapid scale-up and tech transfer
- Formulation, Stability, and Advanced Delivery of Oligo and Peptide Therapeutics
Addressing solubility and aggregation challenges in long-acting peptide formulations

Innovations in formulation and injectables

Novel excipients and technologies for extended-release peptide delivery

Analytical and stability strategies to ensure product integrity and shelf life

Cross-disciplinary lessons from oligo-peptide conjugate development

The deadline for priority consideration is January 23, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: